Supriya Lifescience balance sheet

As of Mar 2025

Total assets: ₹1,112cr+20.7% on Mar 2024
Shareholders' equity: ₹997cr+22.2% on Mar 2024
Total debt: ₹0.0crNo figure a year before
Cash and investments: ₹76.1cr+11.3% on Mar 2024

₹ crore except per share

Tap a line for its trend	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22Mar 2022

Non-current assets
	447	304	255	182
	148	149	67.6	43.4
	1.4	1.7	1.1	1.5
	63.2	63.8	25.3	0.1
	11.2	0.7	0.9	4.0
	675	523	355	237
Current assets
	118	85.2	116	92.3
	134	112	84.7	115
	76.1	68.3	85.3	166
	3.1	6.6	72.3	62.1
	0.9	0.7	0.5	0.6
	0.7	4.5	6.4	6.0
	215	192	249	350
	104	121	99.9	55.5
	437	398	465	498
	1,112	921	820	735
Equity
	16.1	16.1	16.1	16.1
	981	799	683	600
	997	815	699	616
	997	815	699	616
Liabilities
	1.3	0.8	5.9	2.9
	27.0	23.2	13.7	11.1
	33.4	29.0	25.0	19.4
	0.0	0.0	16.6	21.3
	74.5	59.6	64.2	49.0
	1.8	1.6	0.8	0.8
	76.3	61.1	81.7	71.1
	1.2	0.4	0.8	0.4
	4.3	14.9	12.9	27.4
	82.2	76.9	95.8	99.7
	116	106	121	119
	1,112	921	820	735

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

SUPRIYA₹869.30

Supriya Lifescience Ltd.

· Pharma & Health

₹ CrorePeersSTAR SPARC THYROCARE SHILPAMED VIYASH RUBICON YATHARTH PARKHOSPS

View

In ₹ Crore except Per Share As of	FY22 31/03/2022	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	Last 12M 30/06/2026
Non-current Assets
+ Property, Plant & Equipment	182.5	255.1	303.7	446.8	446.8
+ Capital Work-in-Progress	43.4	67.6	148.8	148.0	148.0
+ Other Intangibles	1.5	1.1	1.7	1.4	1.4
+ Non-current Investments	0.1	25.3	63.8	63.2	63.2
+ Other Non-current Assets	4.0	0.9	0.7	11.2	11.2
Total Non-current Assets	237.2	355.4	523.4	675.3	675.3
Current Assets
+ Inventories	92.3	115.8	85.2	118.3	118.3
+ Trade Receivables	115.2	84.7	111.7	134.4	134.4
+ Cash & Cash Equivalents	165.8	85.3	68.3	76.1	76.1
+ Other Bank Balances	62.1	72.3	6.6	3.1	3.1
+ Short-term Loans	0.6	0.5	0.7	0.9	0.9
+ Other Current Financial Assets	6.0	6.4	4.5	0.7	0.7
Current Financial Assets	349.7	249.2	191.8	215.2	215.2
+ Other Current Assets	55.5	99.9	120.7	103.5	103.5
Total Current Assets	497.5	464.9	397.8	437.0	437.0
Total Assets	734.8	820.3	921.2	1,112.3	1,112.3
Equity
+ Equity Share Capital	16.1	16.1	16.1	16.1	16.1
+ Other Equity / Reserves	599.6	683.4	799.3	980.7	980.7
Equity — Owners of Parent	615.7	699.5	815.4	996.8	996.8
Total Equity	615.7	699.5	815.4	996.8	996.8
Liabilities
+ Provisions — Non-current	2.9	5.9	0.8	1.3	1.3
+ Deferred Tax Liabilities	11.1	13.7	23.2	27.0	27.0
Non-current Liabilities	19.4	25.0	29.0	33.4	33.4
+ Borrowings — Current	21.3	16.6	0.0	0.0	0.0
+ Trade Payables	49.0	64.2	59.6	74.5	74.5
+ Other Current Financial Liab	0.8	0.8	1.6	1.8	1.8
Current Financial Liabilities	71.1	81.7	61.1	76.3	76.3
+ Provisions — Current	0.4	0.8	0.4	1.2	1.2
+ Other Current Liabilities	27.4	12.9	14.9	4.3	4.3
Current Liabilities	99.7	95.8	76.9	82.2	82.2
Total Liabilities	119.1	120.8	105.9	115.6	115.6
Total Equity & Liabilities	734.8	820.3	921.2	1,112.3	1,112.3

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY25 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 89%.